With 2.96 trillion USD lost economic output globally in 2020 alone, COVID-19 is estimated as one of the major economical set-backs in the new era. This study aims to calculate the cost of COVID-19 management in Egypt for both prevention (represented in the vaccination program) and management including treatment protocols and indirect cost based on the figures published by the Egyptian ministry of health and population (MOHP). A retrospective excel-based cost-analysis was designed to measure direct and indirect costs of the officially recorded cases and figures only. COVID-19 cases were segmented based on severity to mild with or without hospitalization, moderate, severe, and critical considering their recorded length of stay inside the hospitals. Direct Costs were collected from governmental perspective. Indirect costs included absenteeism and premature mortality following human capital method. Death costs counted for costs of COVID-19 body bags. As per published figures, 514,088 cases and 24,723 deaths were reported, and 90,374,411 vaccine doses were administered till 30th June 2022. The total cost of COVID-19 management in Egypt was estimated to be EGP 46,049,201,088 (USD 2,454,111,899) for both prevention by vaccination, and treatment. The direct medical cost for treatment protocol by medications only was EGP 25,247,679,122 for all disease severities. Indirect costs were EGP 5,087,499,542 with (38%) due to absenteeism and (62%) due to pre-mature death. The prevention arm accounts for EGP 15,714,022,424 for vaccine purchase, storage, supply chain and administration. COVID-19 imposed a huge burden on the Egyptian healthcare system, and these costs only counted for publicly recorded cases. The real costs of the management are expected to be much higher if counting the cases recorded out of the MOHP system either due to self-management or receiving treatment in other than MOHP hospitals.
Read full abstract